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background: The randomized PARTNER trial demonstrated a mortality benefit for transcatheter aortic valve replacement (TAVR) in inoperable 
patients with aortic stenosis (AS). This trial was limited to 23 and 26mm Edwards-SAPIEN valves implanted using a transfemoral (TF) approach. 
Patients with annulus measurements too large for a 26mm valve or inadequate vascular access were excluded. In the PARTNER II trial, we examined 
the outcomes of TF and transapical (TA) TAVR with a 29mm Edwards SAPIEN XT.
Methods: Inoperable patients with AS and annular measurements requiring a 29mm valve determined by computed tomography or 
transesophageal echocardiograpy were enrolled. TF TAVR utilizing a 20Fr esheath or TA TAVR utilizing a 26Fr sheath was performed. Patients were 
followed up to 30 days for this analysis using VARC -2 definitions to categorize outcomes.
results: A total of 107 patients were studied (TF, n=61 and TA, n=46). There were no significant baseline differences between groups. At 30 days, 
acute kidney injury was more common in the TA group, but no other significant differences were observed (Table). The majority of patients (TF, 92.2% 
and TA, 92.3%) had none, trace, or mild paravalvular leak (PVL). A minority (TF, 7.8% and TA, 7.7%) had moderate PVL. No patient had severe PVL.
conclusions: In inoperative patients, TA and TF TAVR utilizing the 29mm Edwards SAPIEN XT are associated with acceptable morbidity and mortality 
at 30 days. There is acceptable PVL rate with no differences between the TA and TF approach.
Characteristic and Outcomes TF (n=61) TA (n=46) P Value
Age 83.29 ± 7.89 (61) 81.69 ± 6.98 (46) 0.28
Male 100.0% (61/61) 97.8% (45/46) 0.43
BSA 2.07 ± 0.22 (61) 2.05 ± 0.22 (46) 0.68
30 day Outcomes
Death 5.0% (3) 9.6% (4) 0.44
Myocardial Infarction 1.6% (1) 0.0% (0) 0.39
Bleeding
Minor
Major
Life-threatening
20.0% (12)
11.7% (7)
3.4% (2)
6.7% (4)
22.6% (10)
11.3% (5)
2.2% (1)
9.1% (4)
0.76
0.93
0.75
0.67
Acute Kidney Injury 10.3% (6) 27.6% (12) 0.03
Vascular complications
Major
Minor
Failure of percutaneous access site
13.2% (8)
8.2% (5)
5.2% (3)
3.4% (2)
11.0% (5)
11.0% (5)
0.0% (0)
0.0% (0)
0.74
0.64
0.13
0.22
Stroke /TIA 0.0% (0) 4.3% (2) 0.1
Coronary Obstruction 1.6%(1) 0.0%(0) 0.39
30 day Paravalvular Aortic Regurgitation
None
Trace
Mild
Moderate
Severe
15.7% (8/51)
45.1% (23/51)
31.4% (16/51)
7.8% (4/51)
0.0% (0/51)
12.8% (5/39)
64.1% (25/39)
15.4% (6/39)
7.7% (3.39)
0.0% (0/39)
0.70
0.07
0.08
1.00
N/A
